These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 17316154

  • 1. Darbepoetin alfa: an effective treatment with flexible and simplified dosing for anemia in patients with cancer.
    Stevenson JG, Natale JJ.
    Pharmacotherapy; 2007 Mar; 27(3):434-46. PubMed ID: 17316154
    [Abstract] [Full Text] [Related]

  • 2. Phase III clinical trials with darbepoetin: implications for clinicians.
    Glaspy J.
    Best Pract Res Clin Haematol; 2005 Mar; 18(3):407-16. PubMed ID: 15792914
    [Abstract] [Full Text] [Related]

  • 3. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B, Silberstein P.
    Oncologist; 2006 Apr; 11(4):409-17. PubMed ID: 16614237
    [Abstract] [Full Text] [Related]

  • 4. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J, Locay H, Scarlata D, Jackson L, Prathikanti R, Audhya P.
    Am J Nephrol; 2006 Apr; 26(2):149-56. PubMed ID: 16636531
    [Abstract] [Full Text] [Related]

  • 5. Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia.
    Glaspy J.
    Oncology (Williston Park); 2006 Jul; 20(8 Suppl 6):29-32. PubMed ID: 16925109
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Darbepoetin alfa for the treatment of cancer-related anemia: an update.
    Pirker R.
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):735-44. PubMed ID: 15485310
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A, Reyes A, Valdés F, Otero A, López de Novales E, Pallardó L, Tabernero JM, Hernández Jaras J, Lladós F.
    Nefrologia; 2003 Oct; 23(2):114-24. PubMed ID: 12778875
    [Abstract] [Full Text] [Related]

  • 11. Effects of darbepoetin alfa administered every two weeks on hemoglobin and quality of life of patients receiving chemotherapy.
    Folloder J.
    Oncol Nurs Forum; 2005 Jan 19; 32(1):81-91. PubMed ID: 15660146
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Darbepoetin alfa: potential role in managing anemia in cancer patients.
    Pirker R, Smith R.
    Expert Rev Anticancer Ther; 2002 Aug 19; 2(4):377-84. PubMed ID: 12647980
    [Abstract] [Full Text] [Related]

  • 14. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ.
    Am J Kidney Dis; 2002 Jul 19; 40(1):110-8. PubMed ID: 12087568
    [Abstract] [Full Text] [Related]

  • 15. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
    Kessler M, Hannedouche T, Fitte H, Cayotte JL, Urena P, Réglier JC, Groupe de l'étude NESP 20000117.
    Nephrol Ther; 2006 Sep 19; 2(4):191-9. PubMed ID: 16966064
    [Abstract] [Full Text] [Related]

  • 16. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R, Bommer J, Braun J, Haag-Weber M, Gill C, Wagner J, Wagener T, German Aranesp Study Group.
    Nephrol Dial Transplant; 2004 May 19; 19(5):1224-30. PubMed ID: 14993489
    [Abstract] [Full Text] [Related]

  • 17. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ, Jacobson DR.
    Ann Pharmacother; 2006 Jan 19; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [Abstract] [Full Text] [Related]

  • 18. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome.
    Patton JF, Sullivan T, Mun Y, Reeves T, Rossi G, Wallace JF.
    J Support Oncol; 2005 Jan 19; 3(6):419-26. PubMed ID: 16350429
    [Abstract] [Full Text] [Related]

  • 19. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
    Nurko S, Spirko R, Law A, Dennis VW.
    Clin Ther; 2007 Sep 19; 29(9):2010-21. PubMed ID: 18035200
    [Abstract] [Full Text] [Related]

  • 20. Darbepoetin alfa: a novel erythropoiesis-stimulating protein.
    Cases A.
    Drugs Today (Barc); 2003 Jul 19; 39(7):477-95. PubMed ID: 12973399
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.